(Q33396908)

26 July 2017

title

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings (English)

1 reference

atypical hemolytic uremic syndrome

26 July 2017

main subject

1 reference

Sibylle Tschumi

1

1 reference

26 July 2017

Mathias Gugger

2

1 reference

26 July 2017

Barbara S Bucher

3

1 reference

26 July 2017

Magdalena Riedl

4

1 reference

26 July 2017

Giacomo D Simonetti

5

1 reference

26 July 2017

language of work or name

1 reference

30 August 2011

1 reference

26 July 2017

1 reference

26 July 2017

volume

26

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

2085-2088

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-011-1989-4

26 July 2017

exact match

0 references

cites work

Genetics and complement in atypical HUS.

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Complement and the atypical hemolytic uremic syndrome in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Eculizumab for congenital atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-011-1989-4

Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21877169

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21877169

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00467-011-1989-4

1 reference

Dimensions Publication ID

26 July 2017

1038525965

0 references

1 reference